Drugs / Recombinant adenovirus type-5-vectored COVID-19 vaccine
Recombinant adenovirus type-5-vectored COVID-19 vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT05373030 | May → Dec 2022 | — | Zhejiang Provincial Center for Disease Control and Prevention | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant adenovirus type-5-vectored COVID-19 vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05373030 ↗ |
| Modality | Vaccine | “Recombinant adenovirus type-5-vectored COVID-19 vaccine” NCT05373030 ↗ |
| Route | Intramuscular | “which are administered intramuscular Ad5-nCoV or inactivated SARS-CoV-2 vaccine (CoronaVac or Covilo).” PMID 37553338 ↗ Aug 2023 |